These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 6128635)

  • 21. Refinement of the prediction of N-acetyltransferase 2 (NAT2) phenotypes with respect to enzyme activity and urinary bladder cancer risk.
    Selinski S; Blaszkewicz M; Ickstadt K; Hengstler JG; Golka K
    Arch Toxicol; 2013 Dec; 87(12):2129-39. PubMed ID: 24221535
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Higher DNA adduct levels in urinary bladder and prostate of slow acetylator inbred rats administered 3,2'-dimethyl-4-aminobiphenyl.
    Jiang W; Feng Y; Hein DW
    Toxicol Appl Pharmacol; 1999 May; 156(3):187-94. PubMed ID: 10222311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between metabolic phenotype of N-acetylation and bladder cancer.
    Cui X; Guo R; Xu Z; Wang B; Li C
    Chin Med J (Engl); 2000 Apr; 113(4):303-5. PubMed ID: 11775223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic susceptibility to bladder cancer.
    Taioli E; Raimondi S
    Lancet; 2005 Aug 20-26; 366(9486):610-2. PubMed ID: 16112283
    [No Abstract]   [Full Text] [Related]  

  • 25. Association Between N-acetyltransferase 2 Polymorphism and Bladder Cancer Risk: Results From Studies of the Past Decade and a Meta-Analysis.
    Wu H; Wang X; Zhang L; Mo N; Lv Z
    Clin Genitourin Cancer; 2016 Apr; 14(2):122-9. PubMed ID: 26585839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer.
    Cartwright RA; Glashan RW; Rogers HJ; Ahmad RA; Barham-Hall D; Higgins E; Kahn MA
    Lancet; 1982 Oct; 2(8303):842-5. PubMed ID: 6126711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Determination of the N-acetyltransferase phenotype in urothelial cancer patients and healthy controls].
    Sone M
    Hinyokika Kiyo; 1986 Aug; 32(8):1085-92. PubMed ID: 3788733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidemiological models of carcinogenesis: the example of bladder cancer.
    Vineis P
    Cancer Epidemiol Biomarkers Prev; 1992; 1(2):149-53. PubMed ID: 1306098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation between N-acetyltransferase activities in uroepithelia and in vivo acetylator phenotype.
    Pink JC; Messing EM; Reznikoff CA; Bryan GT; Swaminathan S
    Drug Metab Dispos; 1992; 20(4):559-65. PubMed ID: 1356735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular epidemiology of bladder cancer.
    Vineis P; Martone T
    Ann Ist Super Sanita; 1996; 32(1):21-7. PubMed ID: 8967722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors.
    Kaisary A; Smith P; Jaczq E; McAllister CB; Wilkinson GR; Ray WA; Branch RA
    Cancer Res; 1987 Oct; 47(20):5488-93. PubMed ID: 3652049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Acetylation phenotype as a biomarker of sensitivity to the carcinogenic effect of aromatic amines].
    Indulski JA; Krajewska B; Lutz W
    Med Pr; 1992; 43(5):427-35. PubMed ID: 1293477
    [TBL] [Abstract][Full Text] [Related]  

  • 33. N-Acetyltransferase phenotypes in the urinary bladder carcinogenesis of a low-risk population.
    Mommsen S; Barfod NM; Aagaard J
    Carcinogenesis; 1985 Feb; 6(2):199-201. PubMed ID: 3971485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acetylator genotype and arylamine-induced carcinogenesis.
    Hein DW
    Biochim Biophys Acta; 1988 Aug; 948(1):37-66. PubMed ID: 3293663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification and kinetic characterization of acetylator genotype-dependent and -independent arylamine carcinogen N-acetyltransferases in hamster bladder cytosol.
    Yerokun T; Kirlin WG; Trinidad A; Ferguson RJ; Ogolla F; Andrews AF; Brady PK; Hein DW
    Drug Metab Dispos; 1989; 17(3):231-7. PubMed ID: 2568902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inheritance of acetylator genotype-dependent arylamine N-acetyltransferase in hamster bladder cytosol.
    Hein DW; Kirlin WG; Yerokun T; Trinidad A; Ogolla F
    Carcinogenesis; 1987 May; 8(5):647-52. PubMed ID: 3581423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NAT2 slow acetylation and bladder cancer in workers exposed to benzidine.
    Carreón T; Ruder AM; Schulte PA; Hayes RB; Rothman N; Waters M; Grant DJ; Boissy R; Bell DA; Kadlubar FF; Hemstreet GP; Yin S; LeMasters GK
    Int J Cancer; 2006 Jan; 118(1):161-8. PubMed ID: 16003747
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acetylation phenotype, carcinogen-hemoglobin adducts, and cigarette smoking.
    Vineis P; Caporaso N; Tannenbaum SR; Skipper PL; Glogowski J; Bartsch H; Coda M; Talaska G; Kadlubar F
    Cancer Res; 1990 May; 50(10):3002-4. PubMed ID: 2334904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.
    Okkels H; Sigsgaard T; Wolf H; Autrup H
    Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):225-31. PubMed ID: 9107426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.
    García-Closas M; Malats N; Silverman D; Dosemeci M; Kogevinas M; Hein DW; Tardón A; Serra C; Carrato A; García-Closas R; Lloreta J; Castaño-Vinyals G; Yeager M; Welch R; Chanock S; Chatterjee N; Wacholder S; Samanic C; Torà M; Fernández F; Real FX; Rothman N
    Lancet; 2005 Aug 20-26; 366(9486):649-59. PubMed ID: 16112301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.